What does Acorda Therapeutics, Inc. do?

Jun 22 2025 06:44 PM IST
share
Share Via
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurological disorders. As of March 2024, it reported net sales of $20 million and a net loss of $27 million, with a market cap of $0.09 million.
Overview:
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders, operating within the Pharmaceuticals: Major industry and classified as a micro-cap company.

Financial Snapshot:
Most recent Net Sales: 20 Million (Quarterly Results - Mar 2024)
Most recent Net Profit: -27 Million (Quarterly Results - Mar 2024)
Market-cap: USD 0.09 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 0.00%
Debt Equity: -0.99
Return on Equity: 7.75%
Price to Book: -0.00

Contact Details:
Address: 420 Saw Mill River Rd, ARDSLEY NY: 10502-2605
Tel: 1 914 3474300
Fax: 1 914 3474560
Website: http://www.acorda.com
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is Acorda Therapeutics, Inc. overvalued or undervalued?
Jun 25 2025 09:00 AM IST
share
Share Via
Most Read